Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of $0.17, $0.02 better than the analyst estimate of $0.15. Revenue for the quarter came in at $157.2 million versus the consensus estimate of $177.94 million.

GUIDANCE:

Corcept Therapeutics sees FY2025 revenue of $900-950 million, versus the consensus of $905.4 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.